Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 juin 2016 12h30 HE | Source: Melinta Therapeutics

Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting

NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
19 mai 2015 16h00 HE | Source: Melinta Therapeutics

Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections

New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative impact of obesity on patients' recovery from acute bacterial skin and skin structure...
09 avr. 2015 12h02 HE | Source: Melinta Therapeutics

Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment

New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of Health-Related Quality-of-Life (HRQL) in acute bacterial skin and skin structure infection...
09 févr. 2015 08h00 HE | Source: Melinta Therapeutics

Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital

New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth...
08 janv. 2015 15h08 HE | Source: Melinta Therapeutics

Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil

NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil, announced that...
07 janv. 2015 13h40 HE | Source: Melinta Therapeutics

Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI

New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...
08 sept. 2014 15h01 HE | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today provided an update on the Company's innovative ESKAPE Pathogen Program. The ESKAPE Pathogen Program leverages Melinta's...

Page précédente